← Resources

Buprenorphine
(Sublingual)

Patient Information Sheet
Dr Basanth Kenchaiah FRANZCP, Cert. Addiction Psych.
General Adult & Addiction Psychiatrist
Delmont Consulting Suites
314 Warrigal Road, Glen Iris VIC 3146
Tel: 03 9834 3600
This sheet provides general information about sublingual buprenorphine (Suboxone®). It is not a substitute for a conversation with your treating doctor. Please ask your doctor or pharmacist if you have any questions specific to your situation.

What is buprenorphine?

Buprenorphine is a medicine used to treat opioid use disorder. It belongs to the opioid class of medicines, but it works differently from opioids such as morphine, oxycodone, or heroin. It is considered a first-line, evidence-based treatment that significantly reduces overdose risk, improves functioning, and supports recovery. Buprenorphine and methadone are the two main medicines used in opioid dependence treatment (ODT), also called opioid substitution therapy (OST).

Sublingual buprenorphine is taken by placing a film or tablet under the tongue (or between the cheek and gum) and allowing it to dissolve. It must not be swallowed; absorption through the gut is very poor.

Suboxone®: buprenorphine with naloxone

Most people are prescribed Suboxone, which contains buprenorphine and naloxone together. The naloxone component is included to deter misuse: if the film is dissolved as directed under the tongue, naloxone has almost no effect. However, if the product is injected, the naloxone is absorbed and can trigger sudden opioid withdrawal.

How does it work?

Buprenorphine is a partial opioid agonist. This means it activates opioid receptors in the brain, which:

Because it binds tightly to opioid receptors (high receptor affinity), it can actually precipitate withdrawal if taken too soon after a full opioid agonist. Your doctor will advise you on timing.

Starting buprenorphine

You will usually be asked to be in mild-to-moderate opioid withdrawal before your first dose (typically a score of ≥8 on the Clinical Opiate Withdrawal Scale). This is to reduce the risk of precipitated withdrawal. Your doctor will guide you through this process and discuss the timing carefully.

There are also low-dose or "microdose" starting protocols available for people who cannot easily stop their current opioid before starting. Your doctor can explain whether this is an option for you.

Dosing

Common side effects

Many side effects settle within the first few weeks. Tell your doctor if they persist or are troublesome.

Important safety information

Do not mix with alcohol, benzodiazepines (e.g. diazepam, alprazolam), or other sedating medicines without discussing with your doctor. This combination can dangerously slow your breathing, even at doses that would normally be safe.

How long will I need to take it?

There is no fixed duration. Many people benefit from taking buprenorphine for an extended period (months to years), and this is associated with better outcomes. Stopping prematurely greatly increases the risk of relapse and overdose. Any decisions about reducing or stopping should be made with your psychiatrist.

Dispensing and prescribing

In Victoria, your prescriber needs a permit for your treatment, and your doses come from one pharmacy that you agree on together. At first, doses are usually taken at the pharmacy, where the pharmacist watches you take them (supervised dosing). As your treatment becomes stable, take-away doses may be arranged. A prescription can include repeats covering up to six months, and your prescriber will still review you regularly.

Other questions?

Please bring any questions to your next appointment. You can also contact the rooms on 03 9834 3600. In an emergency or crisis, call 000 or go to your nearest hospital emergency department.

For a problem with your pharmacy or prescriber that you cannot sort out together, PAMS (Pharmacotherapy Advocacy, Mediation and Support, run by Harm Reduction Victoria) is a free, confidential phone service on 1800 443 844. For alcohol and drug counselling or referral at any hour, call DirectLine on 1800 888 236 (24 hours, free and confidential).

Clinical content informed by: the Australian Government Department of Health, National Guidelines for Medication-Assisted Treatment of Opioid Dependence (2014); the Victorian Department of Health, Victorian Opioid Dependence Treatment Guidelines (2026); and the Therapeutic Goods Administration (TGA) approved product information for Suboxone® (Indivior). These sources are publicly available at health.gov.au, health.vic.gov.au and tga.gov.au.